Tissue Regenix Group (FRA:LSW) Forward PE Ratio: 52.67 (As of Jul. 09, 2026)


FRA:LSW Tissue Regenix Group PLC FRA:LSW
10 GF Score
Price €0.07
GF Value €0.84
! 5 Warning Signs
View Full Analysis

What is Tissue Regenix Group Forward PE Ratio?

Tissue Regenix Group FRA:LSW 10 Forward PE Ratio is 52.67 as of Jul. 09, 2026. GuruFocus rates FRA:LSW with a GF Score™ of 10/100 and a GF Value™ of €0.84. The stock has 5 warning signs investors should review.

Tissue Regenix Group's Forward PE Ratio for today is 52.67.

Tissue Regenix Group's PE Ratio without NRI for today is 0.00.

Tissue Regenix Group's PE Ratio (TTM) for today is 0.00.


Tissue Regenix Group  (FRA:LSW) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Tissue Regenix Group Forward PE Ratio Related Terms


Tissue Regenix Group Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group Forward PE Ratio Chart

Tissue Regenix Group Annual Data
Trend 2023-12 2024-12
Forward PE Ratio
86.21 74.44

Tissue Regenix Group Semi-Annual Data
2023-12 2024-12 2025-06
Forward PE Ratio 86.21 74.44 50.67

FRA:LSW vs VRTX, REGN, ALNY: Forward PE Ratio Comparison

For the Biotechnology subindustry, Tissue Regenix Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tissue Regenix Group Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Forward PE Ratio falls into.


FRA:LSW
10GF Score
Tissue Regenix Group PLC FRA:LSW
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tissue Regenix Group Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 52.67 mean?
Tissue Regenix Group (FRA:LSW) has a Forward PE Ratio of 52.67 as of Jul. 09, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Forward PE Ratio too high?
Tissue Regenix Group's current Forward PE Ratio is 52.67. The Biotechnology industry median Forward PE Ratio is 22.12. Tissue Regenix Group's value of 52.67 is 138.2% above this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Forward PE Ratio compare to VRTX and REGN?
Tissue Regenix Group's Forward PE Ratio of 52.67 can be compared against companies in the Biotechnology industry. The industry median Forward PE Ratio is 22.12. Tissue Regenix Group's value of 52.67 is 138.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.12, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Forward PE Ratio of 52.67 is 138.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Forward PE Ratio is 52.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Forward PE Ratio of 52.67. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Forward PE Ratio is 52.67 and 138.2% above the Biotechnology industry median of 22.12. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Forward PE Ratio is 52.67 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?

Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued. The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.

Key valuation signals for FRA:LSW:

  • Forward PE Ratio: 52.67
  • GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
  • GF Score™: 10/100 with 5 warning signs
  • Industry Position: 138.2% above the Biotechnology median

No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score

Get the complete analysis for FRA:LSW

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.84
GF Value